Some aspects of the preclinical safety of drugs produced by recombinant DNA technology: Japanese government regulatory position.
Hayakawa
T
T
D004274:DNA, Recombinant; D004353:Drug Evaluation, Preclinical; D004926:Escherichia coli / Q000235:genetics; D005818:Genetic Engineering; D006801:Humans; D007564:Japan; D007885:Legislation, Pharmacy; D011994:Recombinant Proteins / Q000592:standards*; D012449:Safety
D004274:DNA, Recombinant; D011994:Recombinant Proteins